Defining gene signatures in colorectal cancer allows researchers to take personalized medicine approach — 3 insights

A study published in Nature Communications discovered how a genomic approach to colorectal cancer could improve a patient's prognosis and quality of life.

Mark Lawler, PhD, lead study author and professor at Belfast, Ireland-based Queen's University, and colleagues showed how defining gene signatures within bowel cancer cells allows for the development of prognostic and predictive bowel cancer markers.

Here's what you should know.

1. Researchers analyzed molecular and genetic data from patients' tissues and "discovered that there are different subtypes of bowel cancer," Dr. Philip Dunne, Queen's University senior research fellow, said in a release.

When researchers identify the cancer cells biological makeup, they can tailor treatments to each specific patient, maximizing effectiveness while limiting side effects.

2. Researchers performed the research as part of the MRC-Cancer Research UK stratified medicine consortium. Several researchers throughout the U.K. were part of the research.

3. The researchers are going to further develop their research with hopes of making it a standard practice.

Copyright © 2022 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Learning Opportunities

Featured Webinars

Featured Whitepapers

Featured Podcast